Gender differences of response to various options of drug therapy in patients with chronic heart failure after suffered myocardial infarction

Cover Page


Cite item

Full Text

Abstract

Aim. To evaluate gender features of treatment in patients with chronic heart failure who suffered myocardial infarction, determine the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers II, as well as antidepressants in the clinico-functional and psycho-emotional status, morphological and functional parameters of the heart in the treatment of men and women with this pathology.

Methods. The study included 205 men and 185 women with chronic heart failure after suffering a myocardial infarction. Patients were randomized into three groups. Patients of the first group (80 men and 70 women) received background treatment (cardiac glycosides, diuretics, aldosterone antagonists, prolonged nitrates if necessary, acetylsalicylic acid, atorvastatin and perindopril 5-10 mg/day. The patients of the second group (80 men and 70 women) received valsartan 80-160 mg/day in addition to the above-noted background treatment. In the therapeutic regimen of the third group of patients (45 men and 45 women) sertraline in a dose of 50 mg/day was included in addition to background treatment. All the patients underwent usual methods of general clinical examination, the 6-minute walk test, clinical status evaluation, the anxiety syndrome severity assessment using a Hamilton scale, echocardiography. The patients dynamic monitoring was carried out for 6 months.

Results. The study results showed that provided therapy has comparable clinical effect in both men and women in all three groups. Statistically significant improvement in clinical condition indicators was reported and as a result, exercise tolerance increased. At the same time the quality of life improvement was more pronounced (p <0.001) in patients of the third group, amid the perindopril and sertraline use. According to the results of our study in patients of all three groups provided therapy has a comparable positive effect on echocardiography indicators, including those which characterize left ventricular hypertrophy.

Conclusion. Amid the provided treatment in all three groups positive dynamics of clinical status indicators and intracardiac dynamics was reported; in addition to that the dynamics of both clinical status and linear and volumetric heart parameters was more pronounced amid the treatment with perindopril in combination with sertraline.

About the authors

G M Dadashova

Scientific-Research Institute of Cardiology named after J. Abdullayev

Author for correspondence.
Email: gulnaz1111@rambler.ru

References

  1. Батурин В.А., Манвелян Э.А., Яровицкий В.Б. Половые особенности потребления психотропных препаратов у больных с депрессивными расстройствами. Пробл. стандартизации в здравоохр. 2008; (9): 30-34.
  2. Болдуева С.А., Третьякова Н.С., Матвеев Д.Г. Ишемическая болезнь сердца у женщин: только ли возрастные различия с мужчинами? Пробл. жен. здоровья. 2006; 1 (1): 64-77.
  3. Верткин А.Л., Сапрыгин Д.Б., Мошина В.А. Роль мозгового натрийуретического пептида (NT-pro BNP) в оценке прогноза и эффективности лечения сердечной недостаточности у больных с острым коронарным синдромом без подьёма сегмента ST. Артериал. гипертенз. 2005; (2): 120-124.
  4. Иванов C.B. Депрессия и сердечно-сосудистая патология. Кардиология. 2009; (7-8): 115-120.
  5. Оганов Р.Г., Погосова Г.В., Шальнова С.А., Деев А.Д. Депрессивные расстройства в общемедицинской практике по данным исследования КОМПАС: взгляд кардиолога. Кардиология. 2005; (8): 37-43.
  6. Перепечко В.П., Аристархова О.Ю. Зайратьянц О.В. и др. Возрастные, половые и гендерспецифические различия в течении социально-значимых заболеваний. Врач скорой помощи. 2011; (3): 7-15.
  7. Тарловская И.И., Суворова Д.А., Соболев А.В. Гендерные различия эффективности гипотензивной терапии: лозартан и эналаприл. Системн. гипертенз. 2012: (2): 19.
  8. Терещенко С.Н., Жиров И.В., Васюк Ю.А., Лебедев A.B. Депрессия после инфаркта миокарда: угроза или гибель? Кардиология. 2007; (8): 93-96.
  9. Apple F.S., Jaffe A.S. Men are different than women; its true for cardiac troponuin too. Clin. Biochem. 2014; 47 (10-11): 867-868. http://dx.doi.org/10.1016/j.clinbiochem.2014.06.008
  10. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 2001; 345 (23): 1667-1675. http://dx.doi.org/10.1056/NEJMoa010713
  11. Dahlöf B., Devereux R.B., Kjeldsen S.E. et al. LIFE Study Group. Lancet. 2002; 359 (9311): 995-1003. http://dx.doi.org/10.1016/S0140-6736(02)08089-3
  12. Dickstein K., Kjekshus J. Comparison of the effects of losartan and captopril on mortality. In: Optimal therapy in myocardial infarction with the angiotensin II antagonist losartan. Am. J. Cardiol. 1999; 83 (4): 477-481. http://dx.doi.org/10.1016/S0002-9149(98)00898-4
  13. Pfeffer M., Braunwald E., Moye L. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 1992; 327: 669-677. http://dx.doi.org/10.1056/NEJM199209033271001
  14. Swedberg K., Granger C. Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM). J. Cardiac. Failure. 1999; 5: 276-282. http://dx.doi.org/10.1016/S1071-9164(99)90013-1

Supplementary files

Supplementary Files
Action
1. JATS XML

© 2016 Dadashova G.M.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.





This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies